Envisioning Arti's 'Cadillac study' to assess aging trajectories in cancer survivors.
The "Cadillac Study" was the term Arti Hurria, MD often used to articulate her vision of the optimal study to investigate the effects of cancer and its treatments on aging trajectories. In her opinion, this study needed to be designed for near-term clinical translation and have the ability to discern subpopulations of cancer survivors at greatest risk for poor outcomes. The purpose of this commentary is to describe, to the best of our knowledge, Arti's Cadillac Study based on personal conversations, group discussions, and her substantial portfolio of research. We describe the necessary study components of the Cadillac Study and discuss approaches to circumvent perceived barriers. In Arti's honor, our goal is to bring awareness and new perspectives to research on the aging consequences of cancer and cancer treatment to move the field forward.